DelveInsight’s “Sickle Cell Disease Pipeline Insights 2026” report provides comprehensive insights about 55+ companies and 60+ drugs in the Sickle Cell Disease Competitive landscape. It covers the Sickle Cell Disease Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead in understanding the Sickle Cell Disease Treatment Landscape @ Sickle Cell Disease Pipeline Outlook
Key Takeaways from the Sickle Cell Disease Pipeline Report
Stay informed about the cutting-edge advancements in Sickle Cell Disease Treatments @ Sickle Cell Disease Clinical Trials Assessment
The Sickle Cell Disease Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Sickle Cell Disease Pipeline Report also highlights the unmet needs with respect to the Sickle Cell Disease.
Sickle Cell Disease Overview
Sickle Cell Disease is the name given for a group of inherited conditions that affect the red blood cells and the most serious type is called Sickle cell anemia. Sickle cells are destroyed rapidly in the bodies of people with the disease, causing anemia which is why it is commonly known as sickle cell anemia. The sickle cells also block the flow of blood through vessels, resulting in lung tissue damage that causes acute chest syndrome, pain episodes, stroke, priapism and damage to the spleen, kidneys and liver.
Sickle Cell Disease Marketed Therapies
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia and continues to advance clinical and research programs in these diseases. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including APOL1-mediated kidney disease, acute and neuropathic pain, type 1 diabetes, myotonic dystrophy type 1 and alpha-1 antitrypsin deficiency.
CASGEVY™ is a non-viral, ex vivo CRISPR/Cas9 gene-edited cell therapy for eligible patients with SCD or TDT, in which a patient’s own hematopoietic stem and progenitor cells are edited at the erythroid specific enhancer region of the BCL11A gene through a precise double-strand break. This edit results in the production of high levels of fetal hemoglobin (HbF; hemoglobin F) in red blood cells. HbF is the form of the oxygen-carrying hemoglobin that is naturally present during fetal development, which then switches to the adult form of hemoglobin after birth. CASGEVY has been shown to reduce or eliminate VOCs for patients with SCD and transfusion requirements for patients with TDT. CASGEVY is approved for certain indications in multiple jurisdictions for eligible patients.
Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease. The company is engaged in the discovery, development and commercialization of innovative treatments and therapies primarily for rare and orphan diseases. The initial efforts have focused on treatments for Sickle Cell Disease, a genetic disorder. Emmaus’s lead commercial product is Endari®, an oral pharmaceutical grade L-glutamine treatment indicated to reduce acute complications of sickle cell disease in adult and pediatric patients five years of age and older.
ENDARI [L-glutamine oral powder] is indicated to reduce the acute complications of sickle cell disease in adults and children 5 years and older. ENDARI is an amino acid indicated to reduce the acute complication of sickle cell disease in adult. The mechanism of action of the amino acid L-glutamine in treating sickle cell disease (SCD) is not fully understood. Oxidative stress phenomena are involved in the pathophysiology of SCD. Sickle red blood cells (RBCs) are more susceptible to oxidative damage than normal RBCs, which may contribute to the chronic hemolysis and vaso-occlusive events associated with SCD. The pyridine nucleotides, NAD+ and its reduced form NADH, play roles in regulating and preventing oxidative damage in RBCs. L-glutamine may improve the NAD redox potential in sickle RBCs through increasing the availability of reduced glutathione.
The Sickle Cell Disease Pipeline Report provides insights into
Get a detailed analysis of the latest innovations in the Sickle Cell Disease pipeline @ Sickle Cell Disease Unmet Needs
Emerging Sickle Cell Disease Drugs Under Different Phases of Clinical Development Include:
Sickle Cell Disease Companies
Pfizer, Editas Medicine, Roche, Quercis Pharma, Graphite Bio, Beam Therapeutics Inc, GlaxoSmithKline, Agios Pharmaceuticals, BRL Medicine, Oryzon Genomics, CorrectSequence Therapeutics, GluBio Therapeutics, Base Therapeutics, and others.
Sickle Cell Disease Pipeline Report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Sickle Cell Disease Products have been categorized under various Molecule types, such as
Stay informed about how we’re transforming the future of Genetic Disorders @ Sickle Cell Disease Market Drivers and Barriers, and Future Perspectives
Scope of the Sickle Cell Disease Pipeline Report
Read the full details of Sickle Cell Disease Pipeline on our website @ Sickle Cell Disease Emerging Drugs and Companies
Table of Contents
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/report-store/sickle-cell-disease-pipeline-insight
